Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$6.01+0.63 (+11.81%)
Close on Nov 17, 2026Market cap $112.45MP/E –Yield –
Trinity Biotech total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Trinity Biotech's total debt was $210.00K at Dec 31, 2025. For fiscal 2025 it was $210.00K, down 50.0% from the year before. Over ten years it grew -45.5% a year on average. The highest annual figure on record is $166.62M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.00K | -50.0% |
| FY2024 | Dec 31, 2024 | $420.00K | 0.0% |
| FY2023 | Dec 31, 2023 | $420.00K | +100.0% |
| FY2022 | Dec 31, 2022 | $210.00K | -99.9% |
| FY2021 | Dec 31, 2021 | $166.62M | +101.6% |
| FY2020 | Dec 31, 2020 | $82.66M | +0.8% |
| FY2019 | Dec 31, 2019 | $82.02M | +0.8% |
| FY2018 | Dec 31, 2018 | $81.38M | -12.5% |
| FY2017 | Dec 31, 2017 | $92.96M | +0.8% |
| FY2016 | Dec 31, 2016 | $92.23M | +0.8% |
| FY2015 | Dec 31, 2015 | $91.51M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $210.00K | -50.0% |
| Q2 FY2025 | Jun 30, 2025 | $210.00K | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $420.00K | +100.0% |
| Q2 FY2024 | Jun 30, 2024 | $210.00K | -99.9% |
| Q4 FY2023 | Dec 31, 2023 | $420.00K | -99.5% |
| Q4 FY2022 | Dec 31, 2022 | $210.00K | -99.7% |
| Q2 FY2022 | Jun 30, 2022 | $210.00K | -99.7% |
| Q4 FY2021 | Dec 31, 2021 | $166.62M | +79.3% |
| Q4 FY2020 | Dec 31, 2020 | $82.66M | -10.4% |
| Q4 FY2019 | Dec 31, 2019 | $82.02M | -10.4% |
| Q4 FY2018 | Dec 31, 2018 | $81.38M | – |
| Q4 FY2017 | Dec 31, 2017 | $92.96M | – |
| Q4 FY2016 | Dec 31, 2016 | $92.23M | – |
| Q4 FY2015 | Dec 31, 2015 | $91.51M | – |
See a number that looks wrong?